UltraGreen.ai Limited told investors at the Citi 2026 ASEAN Summit in Bangkok on Nov, 18 2025 that group revenue rose 59.3% year-on-year to 114.7 million Singapore dollars for FY2024, driven mainly by higher pricing and increased sales volumes of its indocyanine green (ICG) fluorescence imaging products.

Net profit jumped to 56.0 million Singapore dollars, translating to a 48.8% profit margin, while adjusted EBITDA climbed to 71.2 million Singapore dollars with a margin of 62.1%. The company said cash conversion averaged about 71% between 2022 and 1H 2025.

Management highlighted a network of more than 55 distributors selling ICG in 54 countries, with leading market shares in the United States and Europe. Since 2015 the group has supplied about 5.3 million vials of ICG and counts over 18,000 clinical publications and 700 clinical trials that reference the dye.

UltraGreen.ai plans to extend direct sales operations into selected markets, launch its AI-powered PerfusionWorks quantification software—filed for European approval in 2025—and diversify manufacturing and packaging capacity into Asia.

The company is targeting additional growth through new diagnostic products, strategic partnerships and continued investment in research to expand the use of ICG across broader surgical applications.